Introduction: Pramipexole is a new dopaminergic drug which has been approved for PD treatment. However, we tried to find new capacity for this drug rather than symptomatic effect. Materials and Methods: A chronic rotenone model with daily oral dose of 30mg/kg was induced in mice. Pramipexole was tried in a new approach where the treatment began in the middle of rotenone course with oral dose 1mg/kg /day of pramipexole. Results: Further analysis of behavioral tests and immunohistochemistry revealed success of pramipexole in improving the rotenone intoxicated mice. Conclusion: These results showed possible beneficial effect of pramipexole against rotenone induced neurotoxicity.
In the present work we tried pramipexole in the middle of toxic exposure course in a way similar to the natural disease history. In clinical trials pramipexole is given after the manifestations of PD appears (i.e. losing 80% of DA neurons). In such scenario the regenerative capacity is more important. Assessing the neuro-regenrative effects of pramipexole (besides its known neuroprotective effects) was our main question.
2-Materials and methods:
2-1. Rotenone mouse model and drug administration:
Eight-month-old male BALB/c mice (20-25 g) were purchased from vacsera animal house (Cairo, Egypt). All animal experiments were carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals, and the protocols were The mice were pretrained on the apparatus before applying the test.
During the test, a mouse was carefully placed inside the apparatus at 3cm from the top, facing upward, and was allowed to turn around and climb down. The trials were videotaped.
The videos were replayed for analysis of the total time taken for the mouse to make a turn, climb down, and reach the floor by its forepaw. TH-immunopositive neurons in the substantia nigra pars compacta (SNpc) were estimated using stereological counts of cell numbers, on a Stereo-investigator system and optical density measurements on a Leica Q-win system). Six sections (30 µm-thick), from the anterior to the posterior midbrain, were used for counting in each case. The total number of TH-immunopositive neurons was estimated using the optical fractionator method.
2-5 Statistical methods:
All data were given as the mean + standard error of the mean (SEM).
Two groups of data where analyzed by the Student's t-test. Three groups of data were analyzed by ANOVA with a Tukey post hoc test. For all tests, p<0.05 was deemed significant.
3-Results:
3-1. development of progressive PD model:
Regarding the locomotor affection of the mice, the control mice usually take about 10 seconds to complete the vertical grid test. On the other hand, the period increased with progress of time from 14-21-28 th day where the rotenone group has taken more than 80 seconds to complete the test (Table 2A) . This progressive deterioration of locomotor functions of the mice points to the progressive nature of the induced PD model.
As shown in (Fig. 1B) , the oral administration of rotenone at 30 mg/kg for 28 days obviously reduced the number of TH-immunopositive neurons in the SNpc. Stereological analysis of nigral TH-immunopositive neurons showed that rotenone caused a significant loss of DA neurons (Table 1) . It is important to mention that the pilot study showed that the number of TH +ve neurons was decreased with progress of time (after 14 and 21 days), denoting the progressive nature of this model.
3-2. Effect of pramipexole on nigrostriatal DA neurons in rotenone mice
On investigating whether treatment with pramipexole (oral 1 mg/kg/ day for 14 days) can offers neuroprotection against the effects caused by the chronic oral administration of rotenone. The rotenone-induced loss of TH-immunopositive neurons in the SNpc was significantly improved by the pramipexole treatment (Fig. 1B and 1C) .
3-3. Effect of pramipexole on locomotor coordination in rotenone mice.
In our study the control mice usually took about 10 seconds to complete the vertical grid test. On the other hand the rotenone group has taken more than 80 seconds to complete the test (Table 2A) . On studying the effect of treatment we can see that the pramipexole group took about 18 seconds to complete the test which represents a significant improvement in their activity (Table 2B) .
4-Discussion:
One of the major drawbacks of rotenone models for PD was the high mortality rates associated with their parenteral administration ( 
2009).
In this way, the therapy is given in the beginning of the toxic model seems an attractive point of research. However, in the present study we tried to explore the role of pramipexole in a way similar to clinical real life, where the drug is given in the middle of the disease course (i.e. regenerate damaged neurons and at the same time offers neuroprotection for the rest of the others). Our results show that pramipexole improved the disease both functionally (behavioral tests) and structurally (immunohistochemistry). Inden and colleagues have suggested multiple mechanisms for pramipexole effects on PD pathology e.g. inhibition of oligomerization of human wild-type ά-synuclein by H2O2 plus cytochrome c, directly scavenged hydroxyl radical (OH) generated from H2O2 and Fe2+ and increased Bcl-2 immunoreactivity in DA neurons in the SNpc. In the present study we suggest new mechanism which is regeneration of damaged dopaminergic neurons in the SN. This damage is caused by 14 day treatment of rotenone before we began the pramipexole therapy. The regenerated neurons points to the fact that pramipexole can be valuable as neuroregenerative therapy and not only neuroprotectant as suggested by previous studies.
5-Conclusion:
In conclusion, the chronic oral administration of rotenone induced DA neuronal death and was associated with a motor deficit. This pathology was improved by the dopaminergic agent pramipexole that was given in the middle of the toxic model. These results suggest that pramipexole can improve the pathological condition and not just a symptomatic therapy for PD.
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